Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 1/2016

01.01.2016 | Systematic Review

Abuse Potential of Pregabalin

A Systematic Review

verfasst von: Ole Schjerning, Mary Rosenzweig, Anton Pottegård, Per Damkier, Jimmi Nielsen

Erschienen in: CNS Drugs | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Several case reports and epidemiological studies have raised concern about the abuse potential of pregabalin, the use of which has increased substantially over the last decade. Pregabalin is, in some cases, used for recreational purposes and it has incurred attention among drug abusers for causing euphoric and dissociative effects when taken in doses exceeding normal therapeutic dosages or used by alternative routes of administration, such as nasal insufflation or venous injection. The magnitude of the abuse potential and the mechanism behind it are not fully known.

Objective

The aim of this study was to present a systematic review of the data concerning the abuse potential of pregabalin.

Methods

We performed a systematic literature search and reviewed the preclinical, clinical and epidemiological data on the abuse potential of pregabalin.

Results

We included preclinical (n = 17), clinical (n = 19) and epidemiological (n = 13) studies addressing the abuse potential of pregabalin. We also reviewed case reports (n = 9) concerning abuse of pregabalin. The preclinical studies indicated that pregabalin possesses modulatory effects on the GABA and glutamate systems, leaving room for an abuse potential. Further, clinical studies reported euphoria as a frequent side effect in patients treated with pregabalin. The majority of case reports concerning abuse of pregabalin involved patients with a history of substance abuse and, similarly, epidemiological studies found evidence of abuse, especially among opiate abusers.

Conclusions

Overall, the available literature suggests an important clinical abuse potential of pregabalin and prescribers should pay attention to signs of abuse, especially in patients with a history of substance abuse.
Literatur
1.
Montgomery S, Emir B, Haswell H, Prieto R. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability. Curr Med Res Opin. 2013;29:1223–30.PubMedCrossRef
2.
de Guglielmo G, Cippitelli A, Somaini L, Gerra G, Li H, Stopponi S, et al. Pregabalin reduces cocaine self-administration and relapse to cocaine seeking in the rat. Addict Biol. 2013;18:644–53.PubMedCrossRef
3.
4.
5.
Wettermark B, Brandt L, Kieler H, Boden R. Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment. Int J Clin Pract. 2014;68:104–10.PubMedCrossRef
6.
Cho YW, Song ML. Effects of pregabalin in patients with hypnotic-dependent insomnia. J Clin Sleep Med. 2014;10:545–50.PubMedPubMedCentral
7.
Oulis P, Kalogerakou S, Anyfandi E, Konstantakopoulos G, Papakosta VM, Masdrakis V, et al. Cognitive effects of pregabalin in the treatment of long-term benzodiazepine-use and dependence. Hum Psychopharmacol. 2014;29:224–9.PubMedCrossRef
8.
Guglielmo R, Martinotti G, Clerici M, Janiri L. Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther. 2012;29:947–57.PubMedCrossRef
9.
Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52:826–36.PubMedCrossRef
10.
Halaby A, Kassm SA, Naja WJ. Pregabalin dependence: a case report. Curr Drug Saf. 2015;10:184–6.PubMedCrossRef
11.
Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler J, et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol. 2013;69:2021–5.PubMedCrossRef
12.
13.
Expert P. Abuse liability assessment of CNS drugs: conclusions, recommendations, and research priorities. Drug Alcohol Depend. 2003;70(3 Suppl.):S107–14.
14.
Balster RL, Bigelow GE. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 2003;70:S13–40.PubMedCrossRef
15.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.PubMedPubMedCentralCrossRef
16.
Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154:2287–96.PubMedCrossRef
17.
Center for Drug Evaluation and Research US. Consult on abuse potential for NDA review, Lyrica (Pregabalin). In: FaDAP, editor. Review. USA: US Food and Drug Administration; 2004.
18.
Andrews N, Loomis S, Blake R, Ferrigan L, Singh L, McKnight AT. Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference. Psychopharmacology (Berl). 2001;157:381–7.PubMedCrossRef
19.
Rutten K, De Vry J, Robens A, Tzschentke TM, van der Kam EL. Dissociation of rewarding, anti-aversive and anti-nociceptive effects of different classes of anti-nociceptives in the rat. Eur J Pain. 2011;15:299–305.PubMedCrossRef
20.
Stopponi S, Somaini L, Cippitelli A, de Guglielmo G, Kallupi M, Cannella N, et al. Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat. Psychopharmacology (Berl). 2012;220:87–96.PubMedCrossRef
21.
Becker HC, Myrick H, Veatch LM. Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal. Alcohol Alcohol. 2006;41:399–406.PubMedCrossRef
22.
Aracil-Fernandez A, Almela P, Manzanares J. Pregabalin and topiramate regulate behavioural and brain gene transcription changes induced by spontaneous cannabinoid withdrawal in mice. Addict Biol. 2013;18:252–62.PubMedCrossRef
23.
Hasanein P, Shakeri S. Pregabalin role in inhibition of morphine analgesic tolerance and physical dependency in rats. Eur J Pharmacol. 2014;742:113–7.PubMedCrossRef
24.
Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9:792–805.PubMedCrossRef
25.
Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264–73.PubMedCrossRef
26.
Ohta H, Oka H, Usui C, Ohkura M, Suzuki M, Nishioka K. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis Res Ther. 2012;14:R217.PubMedPubMedCentralCrossRef
27.
Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008;35:502–14.PubMed
28.
Nasser K, Kivitz AJ, Maricic MJ, Silver DS, Silverman SL. Twice daily versus once nightly dosing of pregabalin for fibromyalgia: a double-blind randomized clinical trial of efficacy and safety. Arthritis Care Res (Hoboken). 2014;66:293–300.PubMedCrossRef
29.
Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104–10.PubMedCrossRef
30.
Atalay H, Solak Y, Biyik Z, Gaipov A, Guney F, Turk S. Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clin Drug Investig. 2013;33:401–8.PubMedCrossRef
31.
Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33.PubMedPubMedCentralCrossRef
32.
Stacey BR, Barrett JA, Whalen E, Phillips KF, Rowbotham MC. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J Pain. 2008;9:1006–17.PubMedCrossRef
33.
Simpson DM, Schifitto G, Clifford DB, Murphy TK, Durso-De Cruz E, Glue P, et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology. 2010;74:413–20.PubMedPubMedCentralCrossRef
34.
Gilron I, Wajsbrot D, Therrien F, Lemay J. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clin J Pain. 2011;27:185–93.PubMedCrossRef
35.
Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003;160:533–40.PubMedCrossRef
36.
Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005;25:151–8.PubMedCrossRef
37.
Allen R, Chen C, Soaita A, Wohlberg C, Knapp L, Peterson BT, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med. 2010;11:512–9.PubMedCrossRef
38.
Olesen SS, Bouwense SA, Wilder-Smith OH, van Goor H, Drewes AM. Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. Gastroenterology. 2011;141:536–43.PubMedCrossRef
39.
Chew ML, Alvey CW, Plotka A, Pitman VW, Alebic-Kolbah T, Scavone JM, et al. Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies. Clin Drug Investig. 2014;34:627–37.PubMedCrossRef
40.
Lang N, Sueske E, Hasan A, Paulus W, Tergau F. Pregabalin exerts oppositional effects on different inhibitory circuits in human motor cortex: a double-blind, placebo-controlled transcranial magnetic stimulation study. Epilepsia. 2006;47:813–9.PubMedCrossRef
41.
Chua YC, Ng KS, Sharma A, Jafari J, Surguy S, Yazaki E, et al. Randomised clinical trial: pregabalin attenuates the development of acid-induced oesophageal hypersensitivity in healthy volunteers—a placebo-controlled study. Aliment Pharmacol Ther. 2012;35:319–26.PubMedCrossRef
42.
Chew ML, Plotka A, Alvey CW, Pitman VW, Alebic-Kolbah T, Scavone JM, et al. Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies. Clin Drug Investig. 2014;34:617–26.PubMedCrossRef
43.
Filipetto FA, Zipp CP, Coren JS. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc. 2010;110:605–7.PubMed
44.
Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, et al. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry. 2010;167:869.PubMedCrossRef
45.
46.
Yargic I, Ozdemiroglu FA. Pregabalin abuse: a case report/Pregabalin kötüye kullanımı: Bir olgu sunumu. Bull Clin Psychopharmacol. 2011;21:64–6.CrossRef
47.
Skopp G, Zimmer G. Pregabalin—a drug with abuse potential? Arch Kriminol. 2012;229:44–54.PubMed
48.
Carrus D, Schifano F. Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis: two case reports. J Clin Psychopharmacol. 2012;32:839–40.PubMedCrossRef
49.
Papazisis G, Garyfallos G, Sardeli C, Kouvelas D. Pregabalin abuse after past substance-seeking behavior. Int J Clin Pharmacol Ther. 2013;51:441–2.PubMedCrossRef
50.
Gahr M, Franke B, Freudenmann RW, Kolle MA, Schonfeldt-Lecuona C. Concerns about pregabalin: further experience with its potential of causing addictive behaviors. J Addict Med. 2013;7:147–9.PubMedCrossRef
51.
Landmark CJ, Fossmark H, Larsson PG, Rytter E, Johannessen SI. The prescription registry and abuse of pregabalin. Tidsskr Nor Laegeforen. 2011;131:223.PubMedCrossRef
52.
Boden R, Wettermark B, Brandt L, Kieler H. Factors associated with pregabalin dispensing at higher than the approved maximum dose. Eur J Clin Pharmacol. 2014;70:197–204.PubMedCrossRef
53.
Kapil V, Green JL, Le Lait M-C, Wood DM, Dargan PI. Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2014;78:190–1.PubMedPubMedCentralCrossRef
54.
Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin–results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66:947–53.PubMedCrossRef
55.
Gahr M, Freudenmann RW, Hiemke C, Kolle MA, Schonfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;69:1335–42.PubMedCrossRef
56.
Wills B, Reynolds P, Chu E, Murphy C, Cumpston K, Stromberg P, et al. Clinical outcomes in newer anticonvulsant overdose: a poison center observational study. J Med Toxicol. 2014;10:254–60.PubMedPubMedCentralCrossRef
57.
Baird CR, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. Eur Addict Res. 2014;20:115–8.PubMedCrossRef
58.
Jonsson B, Backman E, Salmonson H, Hojer J. Injection of crushed tablets–a prospective observational study. Clin Toxicol (Phila). 2014;52:982–3.PubMedCrossRef
59.
Kriikku P, Wilhelm L, Rintatalo J, Hurme J, Kramer J, Ojanpera I. Pregabalin serum levels in apprehended drivers. Forensic Sci Int. 2014;243:112–6.PubMedCrossRef
60.
Wilens T, Zulauf C, Ryland D, Carrellas N, Catalina-Wellington I. Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. Am J Addict. 2014;24:173–7.CrossRef
61.
Hakkinen M, Vuori E, Kalso E, Gergov M, Ojanpera I. Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Sci Int. 2014;241:1–6.PubMedCrossRef
62.
Launiainen T, Broms U, Keskitalo-Vuokko K, Pitkaniemi J, Pelander A, Kaprio J, et al. Nicotine, alcohol, and drug findings in young adults in a population-based postmortem database. Nicotine Tob Res. 2011;13:763–71.PubMedCrossRef
63.
Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137–50.PubMedCrossRef
64.
Filip M, Frankowska M, Sadakierska-Chudy A, Suder A, Szumiec L, Mierzejewski P, et al. GABAB receptors as a therapeutic strategy in substance use disorders: focus on positive allosteric modulators. Neuropharmacology. 2015;88:36–47.PubMedCrossRef
65.
66.
Tan KR, Brown M, Labouebe G, Yvon C, Creton C, Fritschy JM, et al. Neural bases for addictive properties of benzodiazepines. Nature. 2010;463:769–74.PubMedPubMedCentralCrossRef
67.
Errante LD, Petroff OA. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure. 2003;12:300–6.PubMedCrossRef
68.
Navarrete F, Perez-Ortiz JM, Manzanares J. Pregabalin- and topiramate-mediated regulation of cognitive and motor impulsivity in DBA/2 mice. Br J Pharmacol. 2012;167:183–95.PubMedPubMedCentralCrossRef
69.
70.
Arnold LM, Arsenault P, Huffman C, Patrick JL, Messig M, Chew ML, et al. Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study. Curr Med Res Opin. 2014;30:2069–83.PubMedCrossRef
71.
Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49:661–9.PubMedCrossRef
72.
Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol. 2010;50:941–50.PubMedCrossRef
73.
Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004;24:141–9.PubMedCrossRef
74.
Sugandiran NBJ. Pregabalin may cause dependence even if it is not abused. Arc Cas Rep CMed. 2014;1:1.
75.
Chalabianloo F, Schjott J. Pregabalin and its potential for abuse. Tidsskr Nor Laegeforen. 2009;129:186–7.PubMedCrossRef
76.
Hallas J, Nissen A. Individualized drug utilization statistics. Analysing a population’s drug use from the perspective of individual users. Eur J Clin Pharmacol. 1994;47:367–72.PubMedCrossRef
77.
Hallas J, Stovring H. Templates for analysis of individual-level prescription data. Basic Clin Pharmacol Toxicol. 2006;98:260–5.PubMedCrossRef
78.
Schifano F, D’Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80:118–22.PubMedCrossRef
79.
80.
Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28:491–6.PubMedCrossRef
81.
Papazisis G, Tzachanis D. Pregabalin’s abuse potential: a mini review focusing on the pharmacological profile. Int J Clin Pharmacol Ther. 2014;52:709–16.PubMedCrossRef
82.
Baastrup C, Jensen TS, Finnerup NB. Pregabalin attenuates place escape/avoidance behavior in a rat model of spinal cord injury. Brain Res. 2011;1370:129–35.PubMedCrossRef
Metadaten
Titel
Abuse Potential of Pregabalin
A Systematic Review
verfasst von
Ole Schjerning
Mary Rosenzweig
Anton Pottegård
Per Damkier
Jimmi Nielsen
Publikationsdatum
01.01.2016
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 1/2016
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-015-0303-6

Weitere Artikel der Ausgabe 1/2016

CNS Drugs 1/2016 Zur Ausgabe

Original Research Article

Pharmacokinetics and Clinical Utility of Valproic Acid Administered via Continuous Infusion

Adis Drug Evaluation

Carbidopa/Levodopa ER Capsules (Rytary®, Numient™): A Review in Parkinson’s Disease

Current Opinion

The Benzodiazepine–Dementia Disorders Link: Current State of Knowledge

Review Article

The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review

Systematic Review

A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia

Review Article

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise